Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

To drive global expansion of digital chemistry and discovery, Chemify raises over $50 million in an oversubscribed Series B round

by Lee Cronin to digitalize chemistry at global scale for the benefit of humanity. About Wing Venture Capital Founded in 2013, Wing works with ambitious founders to enable the AI-first transformation of business. We invest early, before it’s...

Successfully deployed in Myanmar conflict zone, the SurgiField system enables life-saving surgery

SurgiBox Inc. announced the successful deployment of its SurgiField System in Myanmar (Burma), where frontline medical teams used the portable surgical technology to perform life-saving procedures in active conflict zones. In a breakthrough...

Mayo Clinic researchers have developed a first-in-kind, fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk

These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...

Illumina's Constellation Mapped Read technology uncovers hard-to-see genomic insights in the GeneDx pilot

already use." For the pilot project, GeneDx used its fleet of NovaSeq X Plus Systems with constellation kits to evaluate 160 DNA samples from individuals with known genetic disease. GeneDx compared samples run with constellation to orthogonal...

CTIBIOTECH™ Partners with SATT AxLR and CILCARE to Develop Inner Ear Organoids for Hearing Disorder Screening

hiPSCs. The CTIBIOTECH™ teams were selected by SATT AxLR for their unique expertise in 3D bioprinting, the fruit of over 15 years of R&D in human tissue biomanufacturing to facilitate the translation and industrial production of this technology at...

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive Alzheimer’s Biomarker Detection

powering precision proteomics to enable the earliest detection of disease, announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal...

FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions

fivefold increase in net sales and a sevenfold rise in operating income since the company joined the Asahi Kasei Group in 2012. In its medium-term management plan, Asahi Kasei has indicated it will capitalize on this steady growth by introducing...

Shanchol® Oral Cholera Vaccine Prequalified by WHO, Ensuring Continuity of Global Supply

Ltd. About Shanchol® Shanchol® is a bivalent killed whole-cell oral cholera vaccine, effective against Vibrio cholerae O1 and O139. It has been a cornerstone of UNICEF-coordinated outbreak responses and preventive immunization campaigns, protecting...

Pharmaceutical Leader Nia Tatsis, Ph.D., Appointed to Odyssey Therapeutics’ Board of Directors

patients in need.” Dr. Tatsis has extensive senior-level leadership experience in global biopharmaceuticals companies. In 2017, Dr. Tatsis joined Vertex Pharmaceuticals and is responsible for managing all aspects of global regulatory affairs and...

Dr. Zivjena Vucetic Appointed as Chief Medical Officer at Mission Bio to Lead Biopharma Partnerships and Clinical Adoption

announced the appointment of Zivjena Vucetic, M.D., Ph.D., as Chief Medical Officer. A physician-scientist with more than 15 years of experience in diagnostics and emerging platforms, Dr. Vucetic has directed medical and scientific strategies that...

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CTx001, the company's lead gene therapy candidate. The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in...

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For...

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV...

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

our position as the global leader of transplant solutions.” Product Launches and Technology Previews at ASHI 2025 AlloSeq Tx11: Launching at ASHI 2025, this next-generation HLA typing solution features enhanced Class II coverage to improve...

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About iCRYO Founded in 2015, iCRYO’s mission is to elevate the quality of life of its team members, guests,...

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is a pill taken twice daily and does not require injections or lab monitoring. It is the...

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

not all of the possible side effects of ENBUMYST. To report suspected adverse reactions, contact Corstasis Therapeutics at 1-877-300-5339 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Corstasis Therapeutics: Corstasis Therapeutics Inc. is...

Leqembi® has received approval for intravenous maintenance treatment in China

mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing...

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

ejection fraction (LVEF) ≥40%, following the agency’s Priority Review of its supplemental New Drug Application (sNDA).1 Since July 2021, KERENDIA has been approved to reduce the risk of CV death, hospitalization for HF, non-fatal myocardial...